CFTR and cystic fibrosis: Correction of CFTR function in CF iLEC with a combination of the Vertex drug compounds VX-809 (corrector, Lumacaftor) and VX-770 (potentiator, Ivacaftor), together known as Orkambi®, an FDA-approved drug for the treatment of CF, showed significant CFTR-specific corrected function (p < 0.01, Fig. 7c,d).